NeuroSense Therapeutics (NeuroSense Therapeutics) FCF Yield % : -40.19 (As of Jun. 07, 2024)

View and export this data going back to 2021. Start your Free Trial

What is NeuroSense Therapeutics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, NeuroSense Therapeutics's Trailing 12-Month Free Cash Flow is $0.00 Mil, and Market Cap is $0.00 Mil. Therefore, NeuroSense Therapeutics's FCF Yield % for today is -40.19%.

The historical rank and industry rank for NeuroSense Therapeutics's FCF Yield % or its related term are showing as below:

NRSNW' s FCF Yield % Range Over the Past 10 Years
Min: -140.12 Med: 0 Max: 222.46
Current: -40.19

During the past 5 years, the highest FCF Yield % of NeuroSense Therapeutics was 222.46%. The lowest was -140.12%. And the median was 0.00%.

NRSNW's FCF Yield % is ranked worse than
72.07% of 1554 companies
in the Biotechnology industry
Industry Median: -14.135 vs NRSNW: -40.19

NeuroSense Therapeutics's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

NeuroSense Therapeutics FCF Yield % Historical Data

The historical data trend for NeuroSense Therapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuroSense Therapeutics FCF Yield % Chart

NeuroSense Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Yield %

NeuroSense Therapeutics Quarterly Data
	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Yield %	Get a 7-Day Free Trial										-	-	-	-	-

Competitive Comparison of NeuroSense Therapeutics's FCF Yield %

For the Biotechnology subindustry, NeuroSense Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NeuroSense Therapeutics's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NeuroSense Therapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where NeuroSense Therapeutics's FCF Yield % falls into.

NeuroSense Therapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

NeuroSense Therapeutics's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-8.481	/
	=	N/A%

NeuroSense Therapeutics's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	0	*	4	/
	=	N/A%

NeuroSense Therapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

NeuroSense Therapeutics FCF Yield % Related Terms

Thank you for viewing the detailed overview of NeuroSense Therapeutics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

NeuroSense Therapeutics (NeuroSense Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeuroSense Therapeutics Ltd (NAS:NRSNW) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

NRSN:USA

Address

11 HaMenofim Street, Building B, Herzliya, ISR, 4676670

Website

https://www.neurosense-tx.com

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.